The quest for effective and safe weight loss solutions has long been a focus of medical research. In recent years, a novel ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Looking at the data from clinical trials of new GLP-1 agonists, it's clear that patients will need to stay on the drugs to ...

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes.

Results of a recent study found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk ...

Securing a prescription for GLP-1s can be pricey — and not to mention, sometimes quite frustrating and invasive. But safety ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

If you’ve been trying to reach a healthier weight, you may be considering semaglutide medications like Ozempic and Wegovy.

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...